CLX

Business profile & competitive position

The Clorox Company operates in the Consumer Defensive sector, specifically the Household & Personal Products industry. It is a multinational manufacturer and marketer of consumer and professional products, reporting fiscal 2026 net sales of roughly $6.7 billion, with about 9,200 employees operating in approximately 25 countries and selling in about 95 markets. Its consumer-facing portfolio includes recognizable brands such as Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt's Bees, while professional products are sold under the Purell, CloroxPro, and Clorox Healthcare names.

The company’s competitive footprint has expanded through the April 2026 completion of the GOJO Industries acquisition, which bolstered Clorox’s health and hygiene portfolio and strengthened its presence in business-to-business channels. However, the financial profile is mixed. Its 8.7% net margin is respectable for a branded consumer staples operation yet well below what would signal wide pricing power. More strikingly, ROE stands at -1,893.5%, a figure that almost always signals deeply negative or minimal shareholders' equity on the balance sheet—often the result of accumulated losses, debt-funded buybacks, or balance-sheet restructuring rather than operating insolvency alone. In practical terms, the company’s book equity is either negative or so small that normal profitability calculations produce an extreme negative number, which is a structural red flag for capital efficiency even as the underlying brands continue to generate cash.

Financial posture

Clorox currently carries a market capitalization of $9.7 billion and trades at a P/E ratio of 16.7, a valuation that sits in a reasonable range for a mature consumer staples name but also reflects the market’s concern about near-term earnings pressure. The stock’s beta of 0.54 confirms its defensive character: it historically moves about half as much as the overall market, consistent with demand for cleaning, pets, charcoal, and salad dressing that does not disappear during economic slowdowns.

The contrast between valuation and profitability metrics is what makes the financial posture unusual. While a 16.7x earnings multiple and an 8.7% net margin would normally describe a stable, low-drama business, the -1,893.5% ROE undercuts that narrative. At a recent price of $80.41, the stock also sits well below its 50-day EMA of $91.67, and its RSI of 29.6 is brushing against the traditional oversold threshold. That technical setup—combined with positive earnings multiples but negative book returns—suggests investors are wrestling with whether Clorox is a temporarily depressed defensive name or a business undergoing a more enduring capital-structure and margin repair process.

Strategic priorities & outlook

In its most recent SEC 10-K filing, Clorox outlined several operational priorities that frame the next few years. The company is executing its IGNITE strategy, which is built around four choices: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio. Translating that into operations, management is focused on completing and optimizing a new enterprise resource planning (ERP) system alongside a broader digital transformation designed to create efficiencies across the supply chain, digital commerce, innovation, and brand building.

On the portfolio side, Clorox intends to invest in strong brands, strategic digital capabilities, and a streamlined operating model to build what it calls a more resilient company capable of delivering consistent, profitable growth. The GOJO integration is a centerpiece of the "health and hygiene" expansion, with management targeting growth in professional and institutional markets. The 10-K also acknowledges a difficult fiscal 2026: organic sales and earnings declined, and diluted EPS fell 26%, partly because macroeconomic headwinds pressured volumes and because ERP transition timing had pulled some sales forward into fiscal 2025. A related structural change occurred on January 31, 2026, when the Glad bags and wraps venture with Procter & Gamble expired, requiring Clorox to purchase P&G's 20% interest; Glad retained core intellectual property licenses on a royalty-free basis.

Macro & geopolitical exposure

As a Consumer Defensive / Household & Personal Products company, Clorox is exposed to a set of industry-level macro forces rather than pure cyclical demand swings. The category generally holds up during recessions because consumers still buy bleach, trash bags, cat litter, and cleaning wipes, but it is not immune to volume pressure when households trade down to private-label alternatives or stretch purchase intervals. Input costs are a persistent factor: resins used in Glad bags, chemicals used in disinfectants, packaging materials, freight, and labor all influence gross margins, and any sustained commodity inflation or supply-chain disruption can compress profitability quickly.

Currency exposure is also material because Clorox sells in about 95 markets, meaning a stronger U.S. dollar can reduce the dollar value of overseas revenue and profit. Regulatory risk runs through the EPA, FDA, and consumer-product safety bodies, since cleaning, health, and personal-care products face labeling, chemical, and environmental rules that can change with little warning. Customer concentration is another structural risk: with Walmart accounting for 26% of fiscal 2026 net sales and the top five customers representing roughly half of consolidated net sales, any pricing dispute, shelf-space reduction, or push for private-label substitution at a major retailer would have an outsized impact.

Recent developments

Recent headlines reflect both the defensive appeal and the operational stress surrounding Clorox. On October 5, 2026, Benzinga published "Wall Street's Most Accurate Analysts Spotlight On 3 Defensive Stocks Delivering High-Dividend Yields," which included Clorox in a defensive-income conversation despite its share-price weakness. On October 3, 2026, two Motley Fool pieces framed the decline: one noted that "Clorox, General Mills, and Constellation Brands Are Down Between 22% and 33%." while another argued that "Clorox is Dealing With Several Years of Challenging Circumstances." A day earlier, on October 2, 2026, Defense World highlighted that "Clorox (NYSE:CLX) Reaches New 52-Week Low – Here's Why."

The price action matches that narrative. With the stock at $80.41, an RSI of 29.6, and a 50-day EMA at $91.67, CLX has broken below a key short-term moving average and is technically oversold. The clustering of "defensive stock" and "new 52-week low" headlines suggests the market is debating whether the valuation compression has created an above-average yield opportunity or whether the multi-year earnings reset still has further to run.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, Clorox has beaten earnings estimates 6 out of 8 times, for a 75% beat rate, with an average earnings surprise of 9.6%. That beat rate would normally be read as a positive earnings-management signal, yet the price response has been uneven. Across those same quarters, the average 5-day price move following earnings has been +1.67%, classified as an "up" post-earnings drift, but the path has not been smooth.

The most recent four quarters illustrate that divergence. On August 3, 2026, Clorox reported $1.66 EPS versus a $1.64 estimate (a 1.2% beat), and the stock rose 6.52% the next day and 9.61% over the following five days. The prior quarter, April 30, 2026, delivered a $1.64 EPS result against a $1.55 estimate (a 5.8% beat), yet the stock fell 9.67% the next day and 4.49% over five days—a reminder that beating the published estimate does not guarantee a positive price reaction. The February 3, 2026 quarter showed the opposite pattern: a -2.8% miss ($1.39 vs. $1.43) was followed by a 2.43% next-day gain and 5.63% five-day gain. Finally, November 3, 2025, produced a 3.9% beat ($0.85 vs. $0.818) with a modest 1.17% next-day rise but a -4.08% five-day drift. The next scheduled release is November 3, 2026, after the close, with the unofficial consensus EPS estimate at $1.09.

For a deeper dive into how sell-side and independent analysts are weighing the GOJO integration, ERP transition, balance-sheet repair, and the November 2026 earnings setup, readers should review the full institutional verdict on Clorox, which aggregates the latest rating changes, estimate revisions, and qualitative notes behind the numbers.